{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:22:19Z","timestamp":1784179339065,"version":"3.55.0"},"reference-count":77,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006041","name":"Innovate UK","doi-asserted-by":"publisher","award":["10011439"],"award-info":[{"award-number":["10011439"]}],"id":[{"id":"10.13039\/501100006041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The incidence and prevalence of neurodegenerative diseases (NDs) are growing worldwide. In an environment where healthcare resources are already stretched, it is important to optimise treatment choice to help alleviate healthcare burden. This rapid review aims to consolidate evidence on factors that influence healthcare professionals (HCPs) to prescribe medication for NDs and map them to theoretical models of behaviour change to identify the behavioural determinants that may support in optimising prescribing.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>Embase and Ovid MEDLINE were used to identify relevant empirical research studies. Screening, data extraction and quality assessment were carried out by three independent reviewers to ensure consistency. Factors influencing prescribing were mapped to the Theoretical Domains Framework (TDF) and key behavioural determinants were described using the Capability, Opportunity, Motivation \u2013 Behaviour (COM-B) model. An initial 3,099 articles were identified, of which 53 were included for data extraction. Fifty-six factors influencing prescribing were identified and categorised into patient, HCP or healthcare system groups, then mapped to TDF and COM-B domains. Prescribing was influenced by capability of HCPs, namely factors mapped to decision making (e.g., patient age or symptom burden) and knowledge (e.g., clinical understanding) behavioural domains. However, most factors were influenced by HCP opportunity, underpinned by factors mapped to social (e.g., prescribing support or culture) and contextual (e.g., lack of resources or medication availability) domains. Less evidence was available on factors influencing the motivation of HCPs<jats:italic>,<\/jats:italic> where evident; factors primarily related to HCP belief about consequences (e.g., side effects) and professional identify (e.g., level of specialism) were often described.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This systematic analysis of the literature provides an in-depth understanding of the behavioural determinants that may support in optimising prescribing practices (e.g., drug costs or pressure from patients\u2019 family members). Understanding these approaches provides an opportunity to identify relevant intervention functions and behaviour change techniques to target the factors that directly influence HCP prescribing behaviour.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0322324","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T17:57:28Z","timestamp":1746554248000},"page":"e0322324","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Behavioural analysis of factors influencing prescribing for neurodegenerative diseases: A rapid review"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-8176","authenticated-orcid":true,"given":"Emma","family":"Begley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7013-8994","authenticated-orcid":true,"given":"Jason","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2155-4139","authenticated-orcid":true,"given":"Carl","family":"Senior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"issue":"3","key":"pone.0322324.ref001","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3390\/ijms23031851","article-title":"A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics","volume":"23","author":"RNL Lamptey","year":"2022","journal-title":"Int J Mol Sci"},{"key":"pone.0322324.ref002","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-981-13-9431-7_17","article-title":"The global economic impact of neurodegenerative diseases: opportunities and challenges.","volume-title":"Bioecon Sust Dev","author":"W Zahra","year":"2020"},{"issue":"5","key":"pone.0322324.ref003","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.3390\/jcm12051709","article-title":"Advances in neurodegenerative diseases","volume":"12","author":"J Van Schependom","year":"2023","journal-title":"J Clin Med"},{"issue":"11","key":"pone.0322324.ref004","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global,regional,and national burden of parkinson\u2019s disease,1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"17","author":"ER Dorsey","year":"2018","journal-title":"Lancet Neurol"},{"issue":"4","key":"pone.0322324.ref005","doi-asserted-by":"crossref","first-page":"a033118","DOI":"10.1101\/cshperspect.a033118","article-title":"Clinical neurology and epidemiology of the major neurodegenerative diseases","volume":"10","author":"MG Erkkinen","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"7","key":"pone.0322324.ref006","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1002\/alz.12901","article-title":"The worldwide costs of dementia in 2019","volume":"19","author":"A Wimo","year":"2023","journal-title":"Alzheimers Dement"},{"key":"pone.0322324.ref007","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41531-020-0117-1","article-title":"Current and projected future economic burden of parkinson\u2019s disease in the U.S","volume":"6","author":"W Yang","year":"2020","journal-title":"NPJ Parkinsons Dis"},{"issue":"18","key":"pone.0322324.ref008","doi-asserted-by":"crossref","first-page":"e1810","DOI":"10.1212\/WNL.0000000000200150","article-title":"The economic burden of multiple sclerosis in the united states: estimate of direct and indirect costs","volume":"98","author":"B Bebo","year":"2022","journal-title":"Neurology"},{"issue":"1","key":"pone.0322324.ref009","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12911-020-1027-1","article-title":"Designing a mHealth clinical decision support system for Parkinson\u2019s disease: a theoretically grounded user needs approach","volume":"20","author":"L Timotijevic","year":"2020","journal-title":"BMC Med Inform Decis Mak"},{"issue":"5","key":"pone.0322324.ref010","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/BF02600099","article-title":"Polypharmacy: the cure becomes the disease","volume":"8","author":"CA Colley","year":"1993","journal-title":"J Gen Intern Med"},{"key":"pone.0322324.ref011","doi-asserted-by":"crossref","first-page":"798916","DOI":"10.3389\/fphar.2022.798916","article-title":"A systematic review of nudge interventions to optimize medication prescribing","volume":"13","author":"U Talat","year":"2022","journal-title":"Front Pharmacol"},{"key":"pone.0322324.ref012","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1748-5908-7-37","article-title":"Validation of the theoretical domains framework for use in behaviour change and implementation research","volume":"7","author":"J Cane","year":"2012","journal-title":"Implement Sci"},{"key":"pone.0322324.ref013","article-title":"The behaviour change wheel: a guide to designing interventions","author":"S Michie","year":"2014"},{"issue":"1","key":"pone.0322324.ref014","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13643-022-02011-5","article-title":"Paper 2: performing rapid reviews","volume":"11","author":"VJ King","year":"2022","journal-title":"Syst Rev"},{"key":"pone.0322324.ref015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jclinepi.2019.06.005","article-title":"Delphi consensus reached to produce a decision tool for selecting approaches for rapid reviews (STARR)","volume":"114","author":"A Pandor","year":"2019","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"pone.0322324.ref016","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"AC Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"pone.0322324.ref017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"D Moher","year":"2015","journal-title":"Syst Rev"},{"key":"pone.0322324.ref018","unstructured":"Hong QN, Pluye P, F\u00e0bregues S, Bartlett G, Boardman F, Cargo M. Mixed methods appraisal tool (MMAT), version 2018. 2018."},{"issue":"3","key":"pone.0322324.ref019","doi-asserted-by":"crossref","first-page":"e000997","DOI":"10.1136\/bmjoq-2020-000997","article-title":"A pharmacist-led pilot using a performance dashboard to improve psychotropic medication use in a skilled nursing facility","volume":"9","author":"K Bell","year":"2020","journal-title":"BMJ Open Qual"},{"key":"pone.0322324.ref020","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.msard.2018.11.023","article-title":"Factors influencing multiple sclerosis disease-modifying treatment prescribing decisions in the United Kingdom: a qualitative interview study","volume":"27","author":"E Cameron","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"pone.0322324.ref021","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2147\/CIA.S146613","article-title":"Prescribing of psychotropic medication for nursing home residents with dementia: a general practitioner survey","volume":"12","author":"JM Cousins","year":"2017","journal-title":"Clin Interv Aging"},{"issue":"8","key":"pone.0322324.ref022","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00228-015-1881-4","article-title":"Trends in inpatient antiparkinson drug use in the USA, 2001-2012","volume":"71","author":"JA Crispo","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"pone.0322324.ref023","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.sapharm.2020.06.006","article-title":"Exploring stakeholder roles in medication management for people living with dementia","volume":"17","author":"AJ Cross","year":"2021","journal-title":"Res Social Adm Pharm"},{"issue":"2","key":"pone.0322324.ref024","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10072-015-2395-7","article-title":"Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline","volume":"37","author":"L Degli Esposti","year":"2016","journal-title":"Neurol Sci"},{"issue":"4","key":"pone.0322324.ref025","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10072-016-2806-4","article-title":"Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs","volume":"38","author":"L Degli Esposti","year":"2017","journal-title":"Neurol Sci"},{"issue":"1","key":"pone.0322324.ref026","first-page":"113","article-title":"Utilization patterns of oral disease-modifying drugs in commercially insured patients with multiple sclerosis","volume":"25","author":"RJ Desai","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"pone.0322324.ref027","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11845-020-02356-7","article-title":"General practitioners\u2019 knowledge of and attitudes towards prescribing psychoactive drugs in dementia care: a cross-sectional questionnaire study","volume":"190","author":"S Dhuny","year":"2021","journal-title":"Ir J Med Sci"},{"issue":"4","key":"pone.0322324.ref028","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00228-019-02820-z","article-title":"Multidisciplinary perspectives on medication-related decision-making for people with advanced dementia living in long-term care: A critical incident analysis","volume":"76","author":"D Disalvo","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"pone.0322324.ref029","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/ijpp.12328","article-title":"Identifying fallacious arguments in a qualitative study of antipsychotic prescribing in dementia","volume":"25","author":"P Donyai","year":"2017","journal-title":"Int J Pharm Pract"},{"issue":"1","key":"pone.0322324.ref030","first-page":"53","article-title":"Use of antidementia medications in Scotland: views of old age psychiatrists.","volume":"24","author":"AC Duthie","year":"2011","journal-title":"GeroPsych: J Gerontopsychol Geriatric Psychiatry"},{"issue":"12","key":"pone.0322324.ref031","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.sapharm.2020.02.016","article-title":"Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data","volume":"16","author":"JR Earla","year":"2020","journal-title":"Res Social Adm Pharm"},{"issue":"3","key":"pone.0322324.ref032","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00044011-200727030-00004","article-title":"Treatment of parkinson\u2019s disease: a survey of patients and neurologists","volume":"27","author":"M Fargel","year":"2007","journal-title":"Clin Drug Investig"},{"issue":"2","key":"pone.0322324.ref033","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40263-013-0133-3","article-title":"A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate alzheimer\u2019s disease in Europe: predictors of discontinuation and switch in the ICTUS study","volume":"28","author":"V Gardette","year":"2014","journal-title":"CNS Drugs"},{"issue":"3","key":"pone.0322324.ref034","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/geront\/gnx178","article-title":"\u201cThe lesser of two evils\u201d versus \u201cmedicines not smarties\u201d: constructing antipsychotics in dementia","volume":"59","author":"D Gill","year":"2019","journal-title":"Gerontologist"},{"issue":"1","key":"pone.0322324.ref035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/mds.10294","article-title":"Treatment of parkinson\u2019s disease in Spain","volume":"18","author":"F Grandas","year":"2003","journal-title":"Mov Disord"},{"issue":"3","key":"pone.0322324.ref036","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3122\/jabfm.2019.03.180335","article-title":"Clinicians\u2019 perspectives on barriers and enablers of optimal prescribing in patients with dementia and coexisting conditions","volume":"32","author":"AR Green","year":"2019","journal-title":"J Am Board Fam Med"},{"key":"pone.0322324.ref037","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2147\/PPA.S53140","article-title":"Treatment selection and experience in multiple sclerosis: survey of neurologists","volume":"8","author":"KA Hanson","year":"2014","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"pone.0322324.ref038","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3233\/JPD-191636","article-title":"Treatment patterns in patients with incident parkinson\u2019s disease in the United States","volume":"9","author":"R Houghton","year":"2019","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"pone.0322324.ref039","first-page":"208","article-title":"Prescribing patterns for Alzheimer disease: survey of Canadian family physicians","volume":"52","author":"M Hillmer","year":"2006","journal-title":"Can Fam Physician"},{"key":"pone.0322324.ref040","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1471-244X-11-190","article-title":"Impact of geriatric comorbidity and polypharmacy on cholinesterase inhibitors prescribing in dementia","volume":"11","author":"F Hoffmann","year":"2011","journal-title":"BMC Psychiatry"},{"issue":"5","key":"pone.0322324.ref041","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1192\/pb.25.5.174","article-title":"Use of a prescribing protocol in routine clinical practice: experience following the introduction of donepezil","volume":"25","author":"J Jari","year":"2001","journal-title":"Psychiatr bull"},{"key":"pone.0322324.ref042","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1471-2377-11-99","article-title":"Prescribing patterns in dementia: A multicentre observational study in a german network of CAM physicians","volume":"11","author":"E Jeschke","year":"2011","journal-title":"BMC Neurol"},{"issue":"1","key":"pone.0322324.ref043","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3122\/jabfm.2018.01.170230","article-title":"Primary care physician perspectives about antipsychotics and other medications for symptoms of dementia","volume":"31","author":"JW Kerns","year":"2018","journal-title":"J Am Board Fam Med"},{"issue":"6","key":"pone.0322324.ref044","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/(SICI)1099-1557(199910\/11)8:6<413::AID-PDS443>3.0.CO;2-5","article-title":"Did knowledge, opinions, background, and health authority advice influence early prescribing of the novel Alzheimer\u2019s disease drug donepezil in general practice?--national postal survey","volume":"8","author":"RM Martin","year":"1999","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"pone.0322324.ref045","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s12603-010-0265-9","article-title":"Assessing physician attitudes and perceptions of Alzheimer\u2019s disease across Europe","volume":"14","author":"P Martinez-Lage","year":"2010","journal-title":"J Nutr Health Aging"},{"issue":"2","key":"pone.0322324.ref046","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/pubmed\/fdu023","article-title":"Second-generation antipsychotic drug use in hospital inpatients with dementia: The impact of a safety warning on rates of prescribing","volume":"37","author":"G McIlroy","year":"2015","journal-title":"J Public Health (Oxf)"},{"issue":"6","key":"pone.0322324.ref047","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/gps.1934","article-title":"Effect of an interdisciplinary educational program on antipsychotic prescribing among nursing home residents with dementia","volume":"23","author":"J Monette","year":"2008","journal-title":"Int J Geriatr Psychiatry"},{"key":"pone.0322324.ref048","first-page":"6293124","article-title":"Evolution of initial pharmacologic treatment of newly diagnosed parkinson\u2019s disease patients over a decade in Singapore","volume":"2020","author":"S Neo","year":"2020","journal-title":"Parkinsons Dis"},{"issue":"3","key":"pone.0322324.ref049","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3233\/JPD-160816","article-title":"Choosing an advanced therapy in Parkinson\u2019s disease; is it an evidence-based decision in current practice","volume":"6","author":"FAP Nijhuis","year":"2016","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"pone.0322324.ref050","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/11588230-000000000-00000","article-title":"The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008","volume":"34","author":"N Ooba","year":"2011","journal-title":"Drug Saf"},{"issue":"2","key":"pone.0322324.ref051","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jsps.2021.01.004","article-title":"Factors affecting the choice of first-line therapy in Parkinson\u2019s disease patients in Wales: a population-based study","volume":"29","author":"K Orayj","year":"2021","journal-title":"Saudi Pharmaceutical J"},{"issue":"2","key":"pone.0322324.ref052","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3138\/cja.26.2.139","article-title":"Physicians\u2019 efficacy requirements for prescribing medications to persons with Alzheimer\u2019s disease","volume":"26","author":"M Oremus","year":"2007","journal-title":"Can J Aging"},{"issue":"3","key":"pone.0322324.ref053","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/08919887231202948","article-title":"Antidementia medication use in nursing home residents","volume":"37","author":"BR Ott","year":"2024","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"8","key":"pone.0322324.ref054","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1017\/S1041610214002816","article-title":"The development and testing of the quality use of medications in dementia (QUM-D): a tool for quality prescribing for behavioral and psychological symptoms of dementia (BPSD)","volume":"27","author":"C Peisah","year":"2015","journal-title":"Int Psychogeriatr"},{"issue":"3","key":"pone.0322324.ref055","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/02813432.2020.1794166","article-title":"Unburdening dementia - a basic social process grounded theory based on a primary care physician survey from 25 countries","volume":"38","author":"F Petrazzuoli","year":"2020","journal-title":"Scand J Prim Health Care"},{"issue":"2","key":"pone.0322324.ref056","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s12325-019-01213-z","article-title":"Alzheimer\u2019s treatment: real-world physician behavior across countries","volume":"37","author":"J Podhorna","year":"2020","journal-title":"Adv Ther"},{"issue":"10","key":"pone.0322324.ref057","doi-asserted-by":"crossref","first-page":"e0205524","DOI":"10.1371\/journal.pone.0205524","article-title":"Comparison of prescribing practices for older adults treated by female versus male physicians: a retrospective cohort study","volume":"13","author":"PA Rochon","year":"2018","journal-title":"PLoS One"},{"key":"pone.0322324.ref058","first-page":"103","article-title":"Do neurologists in Germany adhere to the national Parkinson\u2019s disease guideline?","volume":"7","author":"S Schr\u00f6der","year":"2011","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"11","key":"pone.0322324.ref059","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jamda.2014.08.016","article-title":"Factors related to psychotropic drug prescription for neuropsychiatric symptoms in nursing home residents with dementia","volume":"15","author":"CH Smeets","year":"2014","journal-title":"J Am Med Dir Assoc"},{"issue":"6","key":"pone.0322324.ref060","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.eurger.2014.04.013","article-title":"Prescribing of antipsychotics in people with dementia in acute general hospitals in England: 2010\u20132012","volume":"5","author":"P Stephens","year":"2014","journal-title":"European Geriatric Medicine"},{"issue":"5","key":"pone.0322324.ref061","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1368-5031.2005.00426.x","article-title":"Prescribing pattern in Parkinson\u2019s disease: Are cost and efficacy overriding factors?","volume":"59","author":"EK Tan","year":"2005","journal-title":"Int J Clin Pract"},{"issue":"7","key":"pone.0322324.ref062","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40264-013-0057-3","article-title":"The impact of direct healthcare professional communication on prescribing practice in the UK hospital setting: an interrupted time series analysis","volume":"36","author":"SK Thomas","year":"2013","journal-title":"Drug Saf"},{"issue":"5","key":"pone.0322324.ref063","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.parkreldis.2007.10.010","article-title":"Prescribing pattern of anti-Parkinson drugs in Southern Italy: cross-sectional analysis in the years 2003-2005","volume":"14","author":"G Trifir\u00f2","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"pone.0322324.ref064","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1007\/s00415-022-10969-4","article-title":"Personalizing decision-making for persons with Parkinson\u2019s disease: where do we stand and what to improve?","volume":"269","author":"L van den Heuvel","year":"2022","journal-title":"J Neurol"},{"issue":"5","key":"pone.0322324.ref065","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.3233\/JPD-223208","article-title":"Professionals\u2019 treatment preferences in the prodromal phase of parkinson\u2019s disease: a discrete choice experiment","volume":"12","author":"L van den Heuvel","year":"2022","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"pone.0322324.ref066","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13195-018-0379-6","article-title":"What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink","volume":"10","author":"VM Walker","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"pone.0322324.ref067","doi-asserted-by":"crossref","first-page":"948-958.e12","DOI":"10.1016\/j.jamda.2018.07.004","article-title":"Exploring antipsychotic prescribing behaviors for nursing home residents with dementia: a qualitative study","volume":"19","author":"KA Walsh","year":"2018","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"pone.0322324.ref068","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.parkreldis.2014.10.021","article-title":"Relationships between antiparkinson medication nonadherence,regimen modifications,and healthcare utilization and expenditures","volume":"21","author":"YJ Wei","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"pone.0322324.ref069","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/1533317506294844","article-title":"Family physicians\u2019 recommendations for the treatment of Alzheimer\u2019s disease","volume":"21","author":"P Werner","year":"2006","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"5","key":"pone.0322324.ref070","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/ageing\/afn135","article-title":"Factors influencing the prescribing of medications by old age psychiatrists for behavioural and psychological symptoms of dementia: a qualitative study","volume":"37","author":"A Wood-Mitchell","year":"2008","journal-title":"Age Ageing"},{"issue":"10","key":"pone.0322324.ref071","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1017\/S1041610211001438","article-title":"Psychotropic drug prescription in nursing home patients with dementia: influence of environmental correlates and staff distress on physicians\u2019 prescription behavior","volume":"23","author":"SU Zuidema","year":"2011","journal-title":"Int Psychogeriatr"},{"issue":"5","key":"pone.0322324.ref072","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.3233\/JPD-223208","article-title":"Professionals\u2019 treatment preferences in the prodromal phase of parkinson\u2019s disease: a discrete choice experiment","volume":"12","author":"L van den Heuvel","year":"2022","journal-title":"J Parkinsons Dis"},{"issue":"5","key":"pone.0322324.ref073","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jamia\/ocv192","article-title":"Effects of an e-prescribing interface redesign on rates of generic drug prescribing: exploiting default options","volume":"23","author":"S Malhotra","year":"2016","journal-title":"J Am Med Inform Assoc"},{"issue":"6","key":"pone.0322324.ref074","doi-asserted-by":"crossref","first-page":"e0234149","DOI":"10.1371\/journal.pone.0234149","article-title":"The effectiveness of behavioral economics-informed interventions on physician behavioral change: a systematic literature review","volume":"15","author":"SY Wang","year":"2020","journal-title":"PLoS One"},{"key":"pone.0322324.ref075","first-page":"9237181","article-title":"Patterns and determinants of prescribing for parkinson\u2019s disease: a systematic literature review","volume":"2019","author":"K Orayj","year":"2019","journal-title":"Parkinsons Dis"},{"issue":"7","key":"pone.0322324.ref076","doi-asserted-by":"crossref","first-page":"e048801","DOI":"10.1136\/bmjopen-2021-048801","article-title":"Systematic review of clinician-directed nudges in healthcare contexts","volume":"11","author":"BS Last","year":"2021","journal-title":"BMJ Open"},{"issue":"3 Suppl","key":"pone.0322324.ref077","first-page":"949","article-title":"Factors influencing disease modifying therapy prescribing rates and practices: a qualitative study of neurologists and nurses","volume":"23","author":"E Cameron","year":"2017","journal-title":"Mult Scler J"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0322324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T17:57:44Z","timestamp":1746554264000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0322324"}},"subtitle":[],"editor":[{"given":"Vaibhavi","family":"Peshattiwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":77,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0322324","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]}}}